Your session is about to expire
← Back to Search
Carfilzomib Triplet for Multiple Myeloma (SELECT Trial)
SELECT Trial Summary
This trial is testing a new combination of drugs to treat multiple myeloma.
SELECT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSELECT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 126 Patients • NCT03029234SELECT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My multiple myeloma did not respond to initial treatment.I can take care of myself and perform daily activities.I have been treated with pomalidomide before.I've had proteasome inhibitor treatment before, responded well to carfilzomib, and it's been 6 months since my last dose without major side effects or quick relapse.I have POEMS syndrome.I am 18 years old or older.My multiple myeloma has returned for the first or second time, and I am not responding to my current treatment except for carfilzomib.If you don't have a certain protein in your blood or urine, but your free light chain levels are high and your kappa lambda ratio is abnormal, you may not be eligible.You have a disease that can be measured, and the measurements were taken within the last 28 days before joining the study.You have a certain type of multiple myeloma with a high level of M-protein in your blood.I was diagnosed with amyloidosis linked to myeloma.My condition did not improve after taking lenalidomide.I have been diagnosed with myelodysplastic syndrome.I have primary amyloidosis or multiple myeloma with amyloid deposits but no symptoms.You have more than 200 milligrams of M-protein in your urine over a 24-hour period.I had to stop taking lenalidomide because of its side effects.You have a certain type of multiple myeloma with a high level of a protein in your blood.I have been diagnosed with Waldenström macroglobulinemia.My blood test shows a high number of plasma cells.My condition is IgM subtype multiple myeloma.I have responded positively to at least one previous cancer treatment.
- Group 1: Carfilzomib combined with pomalidomide and dexamethasone
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the estimated enrolment size for this clinical trial?
"At this moment, enrollment for the trial has closed. Initially posted on August 6th 2020, it was updated lastly on July 15th 2022. If you are searching for alternative medical trials, 807 studies related to multiple myeloma and 579 involving Carfilzomib are currently recruiting patients."
Do I qualify to partake in this clinical study?
"This clinical trial is seeking 54 individuals with multiple myeloma, aged between 18 and 99. Eligible subjects must have experienced refractoriness to lenalidamide treatment and achieved partial response (PR) from at least one prior line of therapy. Male or female patients are accepted provided they meet the additional criteria stipulated by International Myeloma Working Group: no relapse within the last 60 days; a minimum 6 month carfilzomib-free interval since their most recent dose; first or second relapse of multiple myeloma according to IMWG standards (subjects unresponsive to previous treatments besides carfilzomib can still"
Has the FDA granted authorization for Carfilzomib?
"Carfilzomib's safety was rated a 2, as there is evidence of its security profile but not yet any indication that it is efficacious."
What other investigations have researchers conducted on Carfilzomib?
"Presently, Carfilzomib has 579 operational trials of which 146 have reached the third stage. In Mishawaka, Indiana alone there are a plethora of clinical sites running studies for this drug and 18925 locations across all states are participating in these experiments."
Are older participants welcomed in this investigation?
"This research is open to individuals aged 18 or above and below 99."
To what conditions is Carfilzomib commonly applied?
"Carfilzomib is typically administered to treat ophthalmia, sympathetic; however, this medication can also be utilized in the management of branch retinal vein occlusion, macular edema and communicable diseases."
Are there any unfilled opportunities for individuals to participate in this experiment?
"Currently, this study is not enrolling candidates. It was first posted on August 6th 2020 and underwent its most recent edit on July 15th 2022. If you're looking for alternatives, 807 trials recruiting patients with multiple myeloma are currently active along with 579 involving Carfilzomib as a treatment option."
How many facilities are managing this clinical experiment?
"At present, patients can be enrolled in this trial at 13 different sites across the United States. These include New Haven, Austin and Denver; alongside 10 other locations. Travelling to your nearest participating clinic is recommended so as to reduce the burden of transportation costs if you do decide to partake."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger